Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.80 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.74 |
| ▸ | JAK3 | P52333 | 3/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.74 |
| ▸ | KDR | P35968 | 7/20 | 0.73 |
| ▸ | CLK1 | P49759 | 1/20 | 0.70 |
| ▸ | LCK | P06239 | 4/20 | 0.69 |
| ▸ | RET | P07949 | 4/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.67 |
| ▸ | GAK | O14976 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | FBP1 | P09467 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570070 | 0.89 | EGFR (0.85) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL5865262 | 0.86 | EGFR (0.81) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL29711485 | 0.85 | JAK3 (1.00) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL29651 | 0.85 | JAK3 (1.00) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL29372372 | 0.85 | JAK3 (1.00) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL1483638 | 0.85 | EGFR (0.71) | EGFRABCG2JAK3KDRCLK1 | |
| SCHEMBL14095971 | 0.85 | EGFR (0.80) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL3533221 | 0.84 | EGFR (0.80) | EGFRABCG2JAK3KDRCLK1 | |
| SCHEMBL5467825 | 0.84 | EGFR (1.00) | EGFRABCG2JAK3ABCB1KDR | |
| SCHEMBL6664095 | 0.84 | EGFR (0.78) | EGFRABCG2JAK3ABCB1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | EGFR 108/4885ABCG2 4067/4885JAK3 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.